steer study semaglutide Three reasons why the #ESC2025 of 2.4 mg versus tirzepatide is not appropriate for drawing conclusions: 1. Semaglutide 2.4 mg should be compared against tirzepatide dosing regimen used for What the SELECT trial of

Our approach includes: Coordinated communication with prescribing physicians to ensure alignment of weight management and physical therapy goals

Experts attribute the increase in reported overdoses to the rapid expansion of prescriptions and growing demand for these medications

Both are exceptional agents with similar actions, and their inclusion depends on individual needs and preferences

Interestingly, the Rybelsus label advises physicians to monitor kidney function in patients who experience serious vomiting

However, these effects are modest and should not be considered a replacement for prescribed medication

doi: 10.1016/j.fochx.2023.100910, 186